drugset
drugset / Trial / NCT06179537

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

NCT06179537 ↗

Phase 1 Completed 34 enrolled Bellus Health Inc. - a GSK company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase I, Double-Blind, Randomised, Adaptive-designed Study to Assess the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Following Single and Multiple Oral Doses

Timeline

Start
2021-08-06
Primary completion
2021-10-22
Completion
2021-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule — Oral

Indications

No indication recorded.